Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

CNBC's Angelica Peebles reports on themes emerging in the pharma space. Republican backs push to repeal part of Trump bill ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

In this week’s edition of InnovationRx, we look at Immuneering’s slow-and-steady approach to cancer fighting, litigation over ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.

Merck to acquire Verona Pharma for $10 billion, adding COPD drug Ohtuvayre to strengthen respiratory portfolio.